Shanghai’s Yonghua Capital, a private equity investor with an interest in life science, led a $25 million Series B funding in Taris Biomedical. Taris is a Boston-area company that is developing implanted, continuous delivery devices combined with known cancer drugs for bladder disease treatment. Bristol-Myers Squibb, one of the other investors in the B round, struck a deal with Taris to test its Opdivo checkpoint inhibitor in combination with Taris’ lead program, TAR-200 (GemRIS™). TAR-200 administers gemcitabine continuously to the bladder for seven days.
Source: China Biotoday
